



8EHQ-0702-15067

RECEIVED
OPPT CBIC

P.O. BOX 385015
BIRMINGHAM, ALABAMA 35238-5015
TELEPHONE (205) 298-3503
FAX (205) 298-2967
E-MAIL: mark.swanson@vul.com

A BUSINESS GROUP OF
VULCAN MATERIALS COMPANY

2002 JUL 23 AM 11:34

MARK S. SWANSON, Ph.D.
MANAGER, TOXICOLOGY
AND PRODUCT STEWARDSHIP

July 18, 2002

MR 60603

Document Processing Center (7407)
Attention: 8(e) Coordinator
Office of Pollution Prevention and Toxics
U.S. Environmental Protection Agency
401 M Street SW
Washington, DC, 20460-0001

Contain NO CBI

RE: Supplemental report: 8EHQ-02-15067 (Chloroalkanes)

Dear 8(e) Coordinator:

This letter notifies U.S. EPA of findings of a recently completed inhalation study with the test substance. The test substance is a by-product of a chemical manufacturing process and is disposed of by incineration.

In this study, male and female rats were exposed by nose-only inhalation to atmospheres of 0.005, 0.01 and 0.1 mg/liter of the test substance for 6 hours per day, 5 days per week, for 4 weeks (a total of 20 exposures).

Findings were as follows: Slight reductions in body weight gain were observed in female rats exposed to 0.01 and 0.1 mg/liter. Prothrombin time was increased in some rats exposed to 0.1 mg/liter. Slight increases in relative kidney weights were observed in male rats in all treatment groups. Histopathological evidence of male rat hydrocarbon nephropathy (increased cortical tubular basophilia and increased cortical tubular hyaline droplets) was observed in male rats in all treatment groups. Effects observed in the male rat kidney did not appear to be dose-related and are believed to be a recognized sex and specie-specific phenomenon. Centrilobular hepatocyte hypertrophy was observed in male rats exposed to 0.1 mg/liter. No treatment-related clinical observations were observed during this study. No unscheduled deaths occurred during the study.

2002 AUG - 1 AM 10:53
RECEIVED
OPPT NCIC

Based on EPA guidance criteria we have concluded that the preliminary findings described in this letter are reportable under TSCA Section 8(e).

Sincerely,

Mark S. Swanson, Ph.D.



8EHQ-02-15067



89020000154

Composition of Test Substance:

Component	CAS Number	Percent
1,1,1,3,5,5-hexachloropentane	18993-24-3	60
1,1,3,3,5,5-hexachloropentane	60027-77-2	31
1,1,1,3,3-pentachloropropane	23153-23-3	5
other isomers of hexachloropentane	N/A	<4